Avoiding deaths in the waiting list for an organ is no longer the only focus of the transplant teams attention. Research and care in clinical practice has been increasingly focused on post transplant graft survival and functioning. In the present work, we performed an integrative literature review to identify the terminology used about liver graft dysfunction and non-function, as well as to investigate the incidence and risk factors of these clinical events. We chosen articles written in Portuguese, English and Spanish between 2012 and 2016, based on CINAHL, MEDLINE, Cochrane, LILACS, BDENF, IBECS, EMBASE and Web of Science. We selected 14 studies, in which we identified the incidence of hepatic graft dysfunction ranging from 7% to 27%. The terminology used to describe this clinical event was initial malfunction, graft hypofunction, marginal function or delay in function. The primary non-function of the liver graft was found in 1.4% to 8.4% of the patients, and the terminology used to describe the event was early dysfunction or graft loss. The risk factors found are related to donor, recipient, graft and transplant logistics variables. We conclude that knowledge of the different terminologies employed in the literature, related to dysfunction and primary non-function incidence, and of their risk factors are fundamental to qualify the control of the events, aiming to improve patients' survival after liver transplantation.
INTRODUCTION
T he most feared event by transplant surgeons is the graft non-functioning after implant [1] [2] [3] [4] [5] [6] .
To describe this condition, the literature uses different nomenclatures, especially in the case of liver transplantation 7 . Liver transplant initiates with removal of the liver to be donated, followed by preparation of the graft and ending with the implant in the recipient. In the removal, when the aorta is clamped, the graft is submitted to devascularization, with prolonged oxygen deprivation and consequent decrease of energy reserves in the tissues. Despite the lack of cellular nutrition, the organ exposed to cold ischemia (ice) maintains its macroscopic morphological aspect unchanged. However, when the aortic artery is unclamped in the recipient and the liver is reperfused, the so-called ischemia- wakefulness, hemodynamic instability, leading to retransplantation or death. This condition has been named as early dysfunction or graft loss and can occur in 0.9% to 7.2% of patients 8, 13 .
In these situations, the literature describes risk factors related to the donor, recipient, graft and the logistics of the transplantation that interfere in the function of the liver graft. However, clinical practice has observed risk factors that need to be better investigated. In this sense, the present study aimed at identifying in the literature the nomenclature used for EGD and PNF of the hepatic graft, their incidence and risk factors. OR "enxerto hepático" OR "Liver Grafting" OR "
METHODS

This is an
Liver Graftings" OR "Transplantação de Fígado" OR "
Transplantação hepática" OR "Hepatic Transplantation"
OR "Transplante Hepático" OR "trasplante hepático") AND ("Disfunção Primária do Enxerto" OR "Primary
Graft Dysfunction" OR "Disfunción Primaria del Injerto"
OR "Não função primária" OR "primary non function"
OR "primary non-function"). For the bases EMBASE, CINAHL, Web of Science and Cochrane were used the following strategy: ("Liver Transplantation" OR "Liver
Grafting" OR "Hepatic Transplantation") AND ("Primary Graft Dysfunction" OR "primary non-function" OR "primary non-function") AND ("Risk Factors" OR "Risk Factor" OR "Risk"). Figure 1 ).
RESULTS
Among the 14 articles selected (Table 1), we observed a fragility from a methodological point of view, since the predominant level of evidence was III, in 12 studies (85.7%).
We found the following nomenclatures in the literature for EGD 7, 17, 18 : poor graft initial function 19, 20 ; early allograft dysfunction, early graft failure 2, 5, 7, 12, 13 ; delayed non-function and impaired primary function 7 . .
The recipient-related risk factors identified in the literature were: pre-transplantation portal vein thrombosis (PVT) cited by two studies 2, 21 . A historical cohort study showed that patients with PVT had a survival rate of 89.6% at three months posttransplantation, and without this comorbidity, a survival rate of 91.5% over the same period of time 21 .
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There was a strong association between some genes and the oxidative stress and apoptosis in liver grafts, by favoring the proliferation of toxic metabolites.
It was concluded that these genes reinforce the marker potential of lipid-related injury and that this fact is important in evaluating graft quality before transplantation 5 .
Regarding the risks related to transplantation logistics, the surgical time and the time between donor asystole and aortic clamping were described in two articles 9, 22 . A study by Taner In this technique, the portal vein is declamped while
The underlying disease (viral C cirrhosis) was found to cause graft failure in two articles 3, 23 . .
We verified that the MELD index, although still used in clinical practice as one that establishes the priority in the queue for transplantation, should not be the isolated indication for the transplant.
Both donor and recipient data should be considered when deciding whether to transplant, for increased patient survival 8, 23 .
Regarding the risks related to the graft, we found: cold shemia time (CIT) >10 hours in four articles 3, 9, 13, 19 , since time below this parameter is considered safe for graft quality. A prospective study of great relevance showed that this factor associated with female gander, donor age >60 years, and infusion of more than 30 fresh frozen plasma units were statistically significant predictors of graft PNF 9 .
Macrosteatosis >30% was a risk factor in three studies 7, 13, 20 . A liver with mild (<30%) steatosis is considered safe to be used for transplantation; a liver with severe steatosis (>60%) should be discarded, and in cases of moderate steatosis (between 30% and 60%), it cautious use is recommended in cases where the recipients have low MELD and low CIT . On her turn, the female donor was identified as a risk factor for PNF 9, 19 .
Hepatic steatosis is classified in the literature as macro and microsteatosis 7, 13, 20 . Donors with BMI=35kgm/m 2 3 may present severe steatosis and, therefore, should not be accepted for liver donation 7 .
However, macrosteatosis up to 30% is safe for use in transplantation 7, 20 . Estimates of the steatosis degree, however, are observer-dependent and, in most cases, histological examination for determination of steatosis percentage is not available for timely evaluation before transplantation 13 . In addition, other authors did not find statistically significant association of steatosis with graft dysfunction 4, 12 , evidencing that the sum of risk factors should be more important than an isolated one. 
Mean donor GGT values of 23 to 50U/l have been pointed as a risk factor for injury 13, 19 . Although the evaluation of an organ based on isolated laboratory data is controversial, a study showed an association of this parameter with graft failure, since the presence of donor comorbidities such as type II diabetes, chronic cardiovascular and renal disease, alcoholism or use of total parenteral nutrition alter the result of the exam 13, 19 . .
Portal vein thrombosis may be a determining factor for post-transplantation evolution due to both its association with thrombophilia and the formation of hepato-fugal shunts. Only part of portal vein thromboses in cirrhotic patients is due to the change in coagulation, since thrombophilia implies a higher incidence of new thrombosis with low graft perfusion and graft dysfunction. On the other hand, the formation of hepato-fugal shunts from the portal circulation is extremely frequent in portal hypertension and, mainly, portal vein thrombosis.
Their relation with graft dysfunction resides on blood flow theft to the collaterals, reducing the graft's portal perfusion, even when the portal trunk has free flow 3, 21 .
The standardization of the anesthetic agent for the liver recipient has been investigated 2, 18 .
Both propofol and sevoflurane are safe for use in liver transplant surgeries 18 . However, propofol has a higher risk for graft dysfunction compared with impacting CIT, which must be taken into account, since it is directly related to graft quality 24 .
Hepatic steatosis is already established as a risk factor for EGD and PNF of the hepatic graft 7, 13, 20 .
It is classified in macro and microsteatosis, and graduated in mild, moderate and severe. Due Regarding the cardiac arrest donor, the time between asystole and aortic perfusion also appears to be associated with graft dysfunction 4, 22 . 24, 25 . Infrastructure shortages also make it impossible to use the risk assessment criteria for an EGD and PNF, and lead to the choice of low quality grafts and donors. Thus, some graft quality evaluation scores evidenced in the present study cannot be applied now for transplant decisions in most Brazilian scenarios.
As for using liver from cardiac arrest donors, it is clear in the literature that liver damage can be reduced in a fast process from a donor with cardiac arrest, compared with the graft exposure to a prolonged low perfusion, while awaiting the entire diagnosis of BD 
CONCLUSION
The present ILR had some limitations, such as the fragility of the evidences of the identified articles and the lack of a standardized language referring to the subject, with a great variation of descriptors, which made the selection of the studies difficult. However, the proposed objectives were achieved, with the identification of various nomenclatures related to EGD and PNF, and their incidences. Risk factors related to donor, recipient, graft and transplantation logistics were also identified. 
